본문으로 건너뛰기
← 뒤로

Effects of Oral Nutritional Supplements in Gastric Cancer Patients with Malnutrition-Sarcopenia Syndrome.

1/5 보강
Nutrition and cancer 📖 저널 OA 0% 2023: 0/4 OA 2025: 0/16 OA 2026: 0/22 OA 2023~2026 2025 Vol.77(10) p. 1132-1141
Retraction 확인
출처

Wu Y, Wu Y, Ding H, Wang Q, Han H, Yu T, Pan Y, Ling Y

📝 환자 설명용 한 줄

Malnutrition and sarcopenia may occur concurrently (Malnutrition-sarcopenia syndrome, MSS) in gastric cancer patients, affecting the prognosis and clinical outcomes.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 95% CI 1.256-4.321
  • OR 2.330
  • HR 1.649

이 논문을 인용하기

↓ .bib ↓ .ris
APA Wu Y, Wu Y, et al. (2025). Effects of Oral Nutritional Supplements in Gastric Cancer Patients with Malnutrition-Sarcopenia Syndrome.. Nutrition and cancer, 77(10), 1132-1141. https://doi.org/10.1080/01635581.2025.2553381
MLA Wu Y, et al.. "Effects of Oral Nutritional Supplements in Gastric Cancer Patients with Malnutrition-Sarcopenia Syndrome.." Nutrition and cancer, vol. 77, no. 10, 2025, pp. 1132-1141.
PMID 40891882 ↗

Abstract

Malnutrition and sarcopenia may occur concurrently (Malnutrition-sarcopenia syndrome, MSS) in gastric cancer patients, affecting the prognosis and clinical outcomes. This study aimed to evaluate MSS prevalence and oral nutritional supplements (ONS) efficacy. This study included a retrospective analysis of 761 gastric cancer patients post-resection to assess MSS prevalence/prognosis, and a prospective non-randomized trial enrolled 81 MSS patients comparing ONS (500 kcal/day ×4 wk) versus standard care. In the retrospective cohort, MSS prevalence was 20.2%, and MSS independently predicted higher postoperative complication (OR: 2.330, 95% CI: 1.256-4.321,  = 0.007), recurrence/metastasis (OR: 4.162, 95% CI: 1.965-8.815,  < 0.001) and worse overall survival (HR: 1.649, 95% CI: 1.007-2.700,  = 0.047). In the prospective trial, ONS significantly improved weight maintenance compared to standard care ( = 0.032). Non-significant trends were observed in ONS group for shorter postoperative length of stay (PLOS) (6.8 vs 8.0 days), fewer complications (5.0% vs 22.0%) and improved handgrip strength (HGS) recovery (0.1 kg vs -0.9 kg). MSS is prevalent in gastric cancer and associated with adverse outcomes. ONS effectively preserves weight and shows recovery benefits, supporting its integration into MSS management.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반